International Urology and Nephrology

, Volume 39, Issue 2, pp 685–689 | Cite as

Anaemia correction in predialysis elderly patients: influence of the antihypertensive therapy on darbepoietin dose

  • Pedro Leão Neves
  • Alexandre Baptista
  • Elsa Morgado
  • Alfonso Iglesias
  • Hermínio Carrasqueira
  • Marília Faísca
  • Carla Soares
  • Ana P. Silva
Original Paper

Abstract

Anaemia and hypertension are common in patients with chronic renal insufficiency. The correction of anaemia with erythropoiesis stimulating agents (ESA) can improve survival and decrease the decline of renal function. Angiotensin converting-enzyme inhibitors (ACEI) and angiotensin II receptor blockers (AIIRA) can also slow the progression of renal failure, but the blockade of the renin-angiotensin system can worsen anaemia. The aim of our study was to assess the impact of antihypertensive therapy (ACEI plus AIIRA) in the requirements of darbepoietin in a group of elderly predialysis patients. We included 71 patients (m = 39, f = 32), mean age of 76.3 years with a mean creatinine clearance of 17.5 ml/min. Patients were divided in two groups according to their antihypertensive therapy: G-I patients under ACEI or AIIRA therapy and G-II normotensive patients or hypertensive patients under antihypertensive drugs other than ACEI or AIIRA. The groups were compared regarding demographic, nutritional, biochemical and inflammatory parameters. We also compared the mean darbepoietin dose. In GI the mean dose of darbepoietin was higher than in GII (0.543 vs. 0.325 µg/kg/week, = 0.032). We did not find any difference regarding other parameters analysed. We conclude that ACEI and AIIRA can increase the needs of darbepoietin in predialysis elderly patients. However, when formally indicated to treat hypertension in a specific patient, they should not be switched to another antihypertensive agent. Instead, in such cases, higher doses of ESA should be used, if necessary.

Keywords

Antihypertensive drugs Darbepoietin Predialysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Samiy AH (1984) Renal disease in the elderly. Med Clin North Am 67:463–480Google Scholar
  2. 2.
    Oreopoulos DG (1990) The aging kidney. Adv Perit Dial 6(Suppl):2–5Google Scholar
  3. 3.
    Raine AEG, Margreiter R, Brunner FP et al (1992) Report on management of renal failure in europe, XXII, 1991. Nephrol Dial Transplant 7(Suppl 2): 7–35Google Scholar
  4. 4.
    Annual report (2002) ESRD clinical performance measures project. Am J Kidney Dis 39(Suppl 2):S4–S98Google Scholar
  5. 5.
    Eschbach JW, Adamson JW (1985) Anemia of end-stage renal disease (ESRD). Kidney Int 28:1–5PubMedCrossRefGoogle Scholar
  6. 6.
    Erslev AJ, Besarab A (1997) Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 51:622–630PubMedCrossRefGoogle Scholar
  7. 7.
    Revised European Best Practice Guidelines (2004) For the management of anaemia in patients with chronic renal failure. Section II: targets for anaemia treatment. Nephrol Dial Transplant 19(Suppl 2):ii6–ii15Google Scholar
  8. 8.
    Acosta JH (1982) Hypertension in chronic renal disease. Kidney Int 22:702–712CrossRefGoogle Scholar
  9. 9.
    Coca A (1998) Actual blood pressure control: are we doing things right ? J Hypertens 16(Suppl 1):S45–S51Google Scholar
  10. 10.
    Juan PC, Weiliang C, Stavros L, Patrick V et al (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033Google Scholar
  11. 11.
    Maschio G, Albert D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zuchelli P (1996) Angiotensin converting enzyme inhibition in progressive renal insufficiency study group. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of renal insufficiency. N Engl J Med 334:939–945PubMedCrossRefGoogle Scholar
  12. 12.
    Plum J, Blunten B, Nemeth R, et al (1998) Effect of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 9:2223–2234PubMedGoogle Scholar
  13. 13.
    Guidelines Committee (2003) 2003 European society of hypertension—European society of cardiology guidelines for the management of hypertension. J Hypertens 21:1011–1053CrossRefGoogle Scholar
  14. 14.
    Chobanian A, Bakris GL, Black HR, et al (2003) The Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. J Am Med Assoc 289:2560–2572CrossRefGoogle Scholar
  15. 15.
    Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T (1984) Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 4:355–360PubMedCrossRefGoogle Scholar
  16. 16.
    Schwarzbeck A, Wittenmeier KW, Hallfritzsch U (1998) Anaemia in dialysis patients as a side-effect of sartanes. Lancet 352:286PubMedCrossRefGoogle Scholar
  17. 17.
    Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H (2003) Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Neprol 23:287–293CrossRefGoogle Scholar
  18. 18.
    Gault MH, Longerich LL, Harnett JD, Wesolowski C (1992) Predicting glomerular function from adjusted serum creatinine (editorial). Nephron 62:249Google Scholar
  19. 19.
    Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC (1999) A modified quantitative subjective global assessmet of nutrition for dialysis patients. Nephrol Dial Transplant 14:1732–1738PubMedCrossRefGoogle Scholar
  20. 20.
    Kuriyama S, Tomonari H, Yoshida H et al (1997) Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176–185PubMedGoogle Scholar
  21. 21.
    Eggers PW (1990) Health care policies/economics of the geriatric renal population. Am J Kidney Dis 16:384–391PubMedGoogle Scholar
  22. 22.
    Friedman EA (2001) Must (should) all ESRD patients be treated? In: Levinsky NG (ed) Ethics and the kidney. Oxford University Press, Oxford, pp 85–98Google Scholar
  23. 23.
    Neves PL, Sousa A, Bernardo I et al (1994) Chronic haemodialysis for very old patients. Age Ageing 23:356–359PubMedCrossRefGoogle Scholar
  24. 24.
    Woodhouse KW, Wynne H, Baille S et al (1988) Who are the frail elderly? Q J Med 255:505–506Google Scholar
  25. 25.
    Revised European Best Practice Guidelines (2004) For the management of anaemia in patients with chronic renal failure. Section IV: failure to respond to treatment. Nephrol Dial Transplant 19(Suppl 2):ii32–ii36Google Scholar
  26. 26.
    Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16(Suppl 3):3–13PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Pedro Leão Neves
    • 1
  • Alexandre Baptista
    • 1
  • Elsa Morgado
    • 1
  • Alfonso Iglesias
    • 1
  • Hermínio Carrasqueira
    • 1
  • Marília Faísca
    • 1
  • Carla Soares
    • 1
  • Ana P. Silva
    • 1
  1. 1.Serviço de NefrologiaHospital Distrital de FaroFaroPortugal

Personalised recommendations